Key Takeaways
- Revenue up 41% YoY, but the number is inflated: The jump was driven primarily by higher input prices passed on to customers, not by underlying volume strength.
- EBITDA surged 79% YoY on mix and inventory gains: Product mix optimisation, monetisation of low-cost inventories, and stable demand combined to lift margins despite elevated raw material prices.
- West Asia disruption was contained, not cured: Exports to the region collapsed from ~15% of revenue to 2%, but a significant portion of volumes was redirected to other markets, limiting the damage.
- Zone IV is late, and FY28 guidance went un-reaffirmed: Management cited 3–6 months of labour and war-related delays, declined to directly reaffirm the lower end of FY28 guidance, and said it remains watchful on ramp-up speed.
- What to watch next quarter: Whether non-energy volumes actually recover as promised, the pace of fuel additives capacity ramp-up, and any signal on how much of the Q1 inventory-linked EBITDA gain reverses.
Zone IV & Growth Projects: The Timeline Slipped
- Zone IV MPP: Multipurpose plant undergoing commissioning now, with first product out expected within August 2026.
- Zone IV other blocks: 97% of equipment erected, 85% of piping complete, and full manpower is back after March–May labour constraints. Commissioning is expected during this financial year, with no further delays anticipated.
- Ramp-up is the real question: The 5 chemistry blocks face slower ramp-up than originally anticipated. Management will share ramp-up details once it has better understanding of the speed, and by FY28 the target is 25–30 products, with 5–10 within this year.
- Customer qualification gated on assets: Pilot-plant product qualification is done with most target customers, but commercial batch requalification can only happen once assets are commissioned.
- Augene JV: Commissioning activities are ongoing, the first raw material sale to the JV has happened, and order book traction is visible. Operations and ramp-up should start within Q2 FY27, with a meaningful PAT difference expected in 2–4 quarters. Steady-state revenue is maintained at ₹300–400 crore, with a higher margin profile than the existing portfolio.
- Eugene Chemicals JV (Superform): Remains firmly on track for commissioning in Q2 FY27, with demand tailwinds in a primary end-use application providing opportunities for faster ramp-up.
- Backward integration project: Civil and building work is ongoing, with commissioning expected around September–October 2027.
- Aarti Circularity (plastic recycling): Slated for commissioning in H2 FY27.
- FY27 capex: Remains on track within the ₹700–800 crore range, with intensity expected to reduce significantly starting FY28 as future capital deployment pivots toward high-growth, high-return niche projects.
Kotecha: "We continue to remain watchful while being fully transparent in terms of where we stand against our strategy. As and when we commission these blocks and we will share the ramp-up phase of these units, once we have a better understanding of what is the speed of ramp-up of these 5 different chemistry blocks."
Energy & Fuel Additives: The Standout Performer
- Demand visibility remains robust: Strong pull is linked to healthy gasoline naphtha cracks at $15–$18/bbl, and demand for the product is "pretty robust" at these levels. Q2 continued strong demand gives confidence that volumes can ramp up irrespective of the Middle East situation.
- Capacity expansion completed: Fuel additives capacity has been expanded to 360 KTPA from 290 KTPA, and utilization is ramping up now, potentially reaching high levels in this quarter itself.
- Stabilisation target: The 360 KTPA capacity is to be stabilised over the next 12 months. The idea is to demonstrate good utilization for this recent expansion and then decide on further increases going forward.
- Portfolio broadening underway: Development and sales efforts have been initiated for new products beyond MMA, aiming to move from one-product dependency to a multiproduct fuel additives portfolio over the next 12 months. Management declined to name the new products at this stage.
- Seasonality risk: Winter seasons are typically weaker, with cracks and demand starting to get impacted around end of October–November–December. Management is evaluating mitigation strategies for volume placements during the lean season.
- Cost position: Management stated it can "very confidently" say the company will be top decile in cost structure for the entire product portfolio being developed in this segment.
- West Asia disruption: The conflict temporarily halted exports to the region, with revenue share falling from ~15% to 2%. A significant portion of volumes was successfully redirected to other markets, and the company expects to regain volumes in upcoming quarters by opening new supply fronts.
Kotecha: "Cost remains sort of in our DNA. We can very confidently say that we will be top decile in terms of cost structure for the entire product portfolio that we are trying to develop as part of this segment."
End-Market Demand: Pockets of Strength, Pockets of Pain
| End-Market | Trend | Commentary |
|---|---|---|
| Energy / Fuel Additives | ▲ Strong | Robust demand at current crack levels; Q2 confidence high irrespective of Middle East. |
| Pharma | ▬ Stable | Demand continues to be stable. |
| Polymers | ▼ Soft in Q1, recovery expected | Weak downstream demand in US & China; Q4 FY26 had bulk US shipments pulling forward volume; pickup expected in Q2 with full-year growth. |
| Agrochemicals | ▼ Marginally lower | Customer resistance to sourcing at elevated raw material prices; volume recovery expected in Q2 on underlying stable demand. |
| Dyes & Pigments | ▼ Subdued | Continued demand headwinds from high raw material pricing and seasonal factors; softening trend over last 3–4 years. |
| NCB value chain | ▲ Favourable opportunity | China's suspension of export tax rebates created favourable conditions; margins recovered in the last quarter after being suppressed for a long time. |
- Non-energy volume drop QoQ: A combination of supply chain issues and purchasing behaviour getting delayed in a high-price environment where inventory wiggle room exists. End consumption demand remains stable, and volumes are expected to pick up during the quarter.
- Long-term contracts: Execution remains stable, continuing to underpin baseline volume growth and safeguard revenue visibility.
Margins & Earnings Quality: Inventory Gains Did Heavy Lifting
- EBITDA growth drivers: The 79% YoY jump came from product mix optimisation, monetisation of low-cost inventories, stable demand, improved realisations for select products, and resilient execution despite temporary disruptions.
- Inventory-linked gains may not recur: Management acknowledged that some inventory-linked gains may not repeat but could be compensated by volume growth. Volume growth is confident; pricing margin and inventory is "anybody's guess" linked to the West Asia situation and pace of pricing movement.
- Gross margin volatility is structural: Within a quarter and within every month, plus/minus 15% price volatility makes quarterly gross margin numbers potentially misleading. Multiple factors are at play: timing of raw material purchase, timing of product placements, forex moves within the quarter, freight expenses, and lower volume leading to higher operating cost in some cases but lower freight cost overall.
- Chemical business runs on absolute deltas: Management emphasised that the business runs on absolute deltas, not on percentage margin, and that behaviour is expected to continue.
- Forex gain of ₹47 crore: Described as a combination of accounting and volatility during the quarter, part of routine business. Drivers included sourcing imported material at higher prices then squaring up at lower rates when the rupee appreciated in April, exports happening at lower rates versus current, and a mark-to-market element from transaction recording rate versus closing rate. The rupee ranged INR 92–97 in the quarter.
- Working capital expanded: Driven by higher feedstock prices and increased export volumes, with debt levels and finance costs rising to support this.
- Inventory risk management: Domestic raw material pricing pass-through is relatively quick at 7–15 days of inventory. Imported raw materials carry 1–1.5 months of inventory, creating price fluctuation exposure. The company uses forward booking of customer orders and hedging strategies to minimise loss.
Kotecha: "The pricing margin and inventory is anybody's guess at this point in time. And frankly, at a management level, it would be difficult to hazard a guess. It is linked to ultimately how the West Asia situation settles and also how rapid is the change in the pricing movement."
Value Chain Margins: A Mixed Bag with a Long-Term Hypothesis
- NCB chain: Margins recovered in the last quarter after being suppressed for a very long time. Price hikes were driven by raw material inflation pass-through and China's VAT removal changing the pricing regime. Some element linked to Chinese government actions might sustain even if raw materials soften. The company will pursue debottlenecking as soon as India consumption potential increases, but is "some time away from demand going to a level where we need asset expansion."
- DCB chain: DCB hydrogenation has always had decent margins. The company is looking to debottleneck to 140 KTPA backed by volume increase supported by PDCB and downstream demand.
- NT chain: Remains suppressed due to an isomer imbalance over the last 2–3 years. Innovative strategies are being deployed to rebalance the portfolio.
- PDA chain: Structurally weak because of a technological disadvantage. The company is working on cost efficiencies to improve the margin profile.
- Industry-level margin restructuring hypothesis: Management's personal view is that if capacity rationalisation continues, post-2028 or 2029 demand could pick up, utilisation levels could become healthy globally, and margin profiles could fundamentally restructure. But "we have to wait at least 2 or 3 more years to see if it pans out."
Kotecha: "If this behavior continues, we potentially could see post '28, '29 kind of a time frame where demand kind of picks up a pace and it starts reaching closer to capacities and the utilization level starts becoming healthy at a global level. We could fundamentally see restructuring of the margin profile at the industry level. But that is a personal hypothesis, and I guess we have to wait at least 2 or 3 more years to see if it pans out."
Disclosure & Transparency: Volume Numbers Pulled
- Volume numbers removed from presentation: Management confirmed it removed actual sales numbers from slides because they were "getting utilized in a situation which was not favourable for the company." Only energy/non-energy growth percentages and utilisation ranges are now provided.
- Geographic and product detail declined: Management declined to provide the average geographical distribution of the energy business, the target addressable market in the US for MMA, and the names of new fuel additive products beyond MMA.
- Customer-specific questions deflected: When asked about SABIC backward integration, management stated, "We do not talk about a specific customer name linked to a specific contract."
Kotecha: "The actual sales numbers is something that we have removed from the slides because they was getting utilized in a situation which was not favourable for the company."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Zone IV other blocks commissioning | 97% equipment erected, 85% piping complete; full manpower back | During FY27 |
| Zone IV MPP first product | Product out expected | Within August 2026 |
| Augene JV operations start | Operations and ramp-up to begin | Within Q1 FY27 |
| Augene JV PAT contribution | Meaningful PAT difference expected | 2–4 quarters from Q1 FY27 start |
| Eugene Chemicals JV commissioning | Firmly on track | Q2 FY27 |
| Aarti Circularity commissioning | Plastic recycling with Re Sustainability | H2 FY27 |
| Backward integration project commissioning | Civil and building work ongoing | September–October 2027 |
| FY27 capex | On track | ₹700–800 crore range |
| Fuel additives capacity stabilisation | 360 KTPA to be stabilised | Over the next 12 months |
| Fuel additives portfolio broadening | Move from one-product to multiproduct portfolio | Over the next 12 months |
| Capex intensity reduction | Significant reduction in capital deployment, pivot to niche high-return projects | Starting FY28 |
| Non-energy volume recovery | End consumption demand stable, volumes expected to pick up | During Q2 FY27 |
| Polymer segment recovery | Pickup expected in Q2; full-year growth | Q2 FY27 and full year |
| Agrochemicals volume recovery | Supported by underlying stable demand | Q2 FY27 |
| West Asia volume recovery | Regain volumes by opening new supply fronts | Upcoming quarters |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹2,627 cr, +41% YoY |
| EBITDA | ₹385 cr, +79% YoY |
| Profit After Tax | ₹155 cr, +260% YoY |
| EBITDA margin | 14.7% (per an analyst's math), versus 11.5% in Q1 FY26 |
| Forex gain | ₹47 cr, included in EBITDA |
| Inventory and FX gain impact | ₹50–60 cr combined, management estimate |
| Exports share of revenue | 59% |
| Energy business volumes | down 17% QoQ |
| Non-energy business volumes | down 7% QoQ |
| Overall volumes | down ~12% QoQ |
| West Asia revenue share | 2%, declined from ~15% |
| Fuel additives capacity | 360 KTPA, expanded from 290 KTPA |
| Gasoline naphtha cracks | $15–$18 per barrel average, healthy |
| Q1 FY27 capex deployed | ~₹180 cr, within FY27 guidance of ₹700–800 cr |
| Zone IV equipment erected | 97%; piping complete: 85% |